451 related articles for article (PubMed ID: 17671176)
1. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
2. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
[TBL] [Abstract][Full Text] [Related]
3. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
5. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers.
Imoto I; Izumi H; Yokoi S; Hosoda H; Shibata T; Hosoda F; Ohki M; Hirohashi S; Inazawa J
Cancer Res; 2006 May; 66(9):4617-26. PubMed ID: 16651412
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
7. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
Bignone PA; Lee KY; Liu Y; Emilion G; Finch J; Soosay AE; Charnock FM; Beck S; Dunham I; Mungall AJ; Ganesan TS
Oncogene; 2007 Feb; 26(5):683-700. PubMed ID: 16878154
[TBL] [Abstract][Full Text] [Related]
8. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation.
Takada H; Imoto I; Tsuda H; Nakanishi Y; Ichikura T; Mochizuki H; Mitsufuji S; Hosoda F; Hirohashi S; Ohki M; Inazawa J
Oncogene; 2005 Dec; 24(54):8051-60. PubMed ID: 16103878
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer.
Yanaihara N; Nishioka M; Kohno T; Otsuka A; Okamoto A; Ochiai K; Tanaka T; Yokota J
Int J Cancer; 2004 Oct; 112(1):150-4. PubMed ID: 15305387
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
12. PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation.
Suzuki E; Imoto I; Pimkhaokham A; Nakagawa T; Kamata N; Kozaki KI; Amagasa T; Inazawa J
Oncogene; 2007 Dec; 26(57):7921-32. PubMed ID: 17599052
[TBL] [Abstract][Full Text] [Related]
13. Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma.
Nakamura E; Kozaki K; Tsuda H; Suzuki E; Pimkhaokham A; Yamamoto G; Irie T; Tachikawa T; Amagasa T; Inazawa J; Imoto I
Cancer Sci; 2008 Jul; 99(7):1390-400. PubMed ID: 18452558
[TBL] [Abstract][Full Text] [Related]
14. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Yamada H; Yamamoto R; Sakuragi N; Enokida H; Verma M; Dahiya R
Cancer; 2005 Nov; 104(9):1924-30. PubMed ID: 16134181
[TBL] [Abstract][Full Text] [Related]
15. Expression of connective tissue growth factor in pancreatic cancer cell lines.
Kwon S; Munroe X; Crawley SC; Lee HY; Spong S; Bradham D; Gum JR; Sleisenger MH; Kim YS
Int J Oncol; 2007 Oct; 31(4):693-703. PubMed ID: 17786299
[TBL] [Abstract][Full Text] [Related]
16. Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Risberg B; Ben-Baruch G; Reich R
Cancer Metastasis Rev; 2003 Mar; 22(1):103-15. PubMed ID: 12716042
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
18. Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia.
Pradjatmo H
Asian Pac J Cancer Prev; 2015; 16(18):8599-604. PubMed ID: 26745123
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
[TBL] [Abstract][Full Text] [Related]
20. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
Wu R; Hendrix-Lucas N; Kuick R; Zhai Y; Schwartz DR; Akyol A; Hanash S; Misek DE; Katabuchi H; Williams BO; Fearon ER; Cho KR
Cancer Cell; 2007 Apr; 11(4):321-33. PubMed ID: 17418409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
